Concept Life Sciences and Accelero Biostructures have partnered to advance drug development through Accelero's range of structural biology platforms.
Together, the companies aim to speed up the drug development process by up to 10x by utilising high-throughput protein X-ray crystallography.
According to Accelero, X-ray crystallography is essential in understanding protein-ligand interactions during structural-based drug discovery, allowing precise hit identification and target engagement validation.
This process is bolstered by Accelero's AI-driven drug discovery platforms, which further aim to accelerate the path from screening to drug candidate selection.
Through this novel partnership, Concept will combine its integrated drug discovery processs with Accelero's fragment screening capabilities, which will assist their customers in hit generation and inhibitor optimisation.
This will bolster both companies' hit-to-lead development capacities, with the aim of reducing development timelines and facilitate the movement of a compound from discovery to clinical trials.
Debanu Das, Co-Founder and CEO of Accelero Biostructures, commented: “This collaboration brings together two teams dedicated to pushing the boundaries of what’s possible in drug discovery. By uniting our expertise, we’re equipped to tackle complex challenges in a way that enhances the quality and pace of discovery. We’re excited to have already initiated several collaborative projects and look forward to seeing their impact.”
Ben Cliff, CEO of Concept Life Sciences, added: “Partnering with Accelero allows us to leverage our combined capabilities in a way that strengthens support for biopharma companies aiming to advance new therapies. This alliance underscores our commitment to driving scientific rigour and efficiency, ultimately helping more candidates progress smoothly through the discovery pipeline.”
[Image credit: Jeff Dahl]